Fig.7

EphA3 expression correlates with poor clinical outcomes and pro-migratory and invasive genes in ER-positive BC patients. A Box plot showing the differential EphA3 expression levels in ER-positive and negative BC patients, as found in the TCGA dataset. B EphA3 mRNA levels according to BC intrinsic molecular subtypes of the TCGA cohort. The number of patients is reported in each panel. Kaplan–Meier plots showing the association of EphA3 expression with the overall survival (OS) (C) and disease specific survival (DSS) (D) of the TCGA ER-positive BC patients. Patients were divided into EphA3 high and low categories using the optimum cut-off. E Kaplan–Meier plot showing the association of EphA3 expression with the OS of ER-positive BC patients characterized by high RAGE expression levels (above the 3Q). Patients were divided into EphA3 high and low categories using the optimum cut-off. KEGG pathway (F) and gene ontology (GO) (G-I) analyses depicting the association of EphA3 expression with pro‐metastatic pathways and GO terms in ER‐positive BC samples of TCGA. The x-axes and the y-axes indicate respectively the -log10 p-value and the different KEGG pathways and GO terms. Lum A, Luminal A; Lum B, Luminal B; ns, not significant; (**) indicates p < 0.01; (***) indicates p < 0.001 and (****) indicates p < 0.0001